Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Change in Inventory (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Change in Inventory for 15 consecutive years, with -$2.8 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory fell 8.11% to -$2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.0 million through Dec 2025, up 48.14% year-over-year, with the annual reading at -$5.0 million for FY2025, 48.14% up from the prior year.
  • Change in Inventory hit -$2.8 million in Q4 2025 for Ligand Pharmaceuticals, up from -$3.6 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $13.0 million in Q2 2023 to a low of -$9.7 million in Q2 2022.
  • Historically, Change in Inventory has averaged -$768400.0 across 5 years, with a median of -$1.6 million in 2022.
  • Biggest five-year swings in Change in Inventory: surged 872.98% in 2021 and later crashed 4525.0% in 2023.
  • Year by year, Change in Inventory stood at -$2.7 million in 2021, then soared by 49.33% to -$1.4 million in 2022, then surged by 47.86% to -$707000.0 in 2023, then tumbled by 262.94% to -$2.6 million in 2024, then decreased by 8.11% to -$2.8 million in 2025.
  • Business Quant data shows Change in Inventory for LGNDZ at -$2.8 million in Q4 2025, -$3.6 million in Q3 2025, and $875000.0 in Q2 2025.